Earlier this week, a small San Diego company named Organovo (NASDAQ:ONVO) filed its annual report with the SEC. Since then, shares have traded down by as much as 18%.
This appears to be in response to a posting on Seeking Alpha which opined that "Management's obfuscation in its reporting underscores its controversial nature. It undermines management's credibility and lends credence to bears' view that its long-term value proposition of printing human organs is a myth."
While Organovo is often referred to as a company with such a goal, this goal has been thoroughly discussed and is actually a very small part of what the company hopes to accomplish in the near future.
In the slide show below, we'll examine the two big take-aways from the company's report, and whether or not it warrants such a price correction.
Brian Stoffel owns shares of Organovo, though they make up less than 0.1% of his overall holdings. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.